US FDA approves Giapreza to treat dangerously low blood pressure


eMediNexus    22 December 2017

The US Food and Drug Administration (FDA) has approved Giapreza (angiotensin II) as intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock. Giapreza can cause dangerous blood clots with serious consequences, so, prophylactic treatment for blood clots should be used.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.